Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Bexxar: encouraging interim phase III data reported

May 14, 1998

DAB389IL-7, a novel fusion protein for the specific elimination of IL-7 receptor-positive cells

May 12, 1998

Patient enrollment begins for U.S. trial of Maxamine in malignant melanoma

May 11, 1998

Multikine clinical trials update

May 11, 1998

Genentech files for marketing approval of Herceptin

May 5, 1998

Biomira initiates bridging study of Theratope cancer vaccine

May 4, 1998

Efficacy of StressGen's HspE7 in preclinical cancer models reported at FASEB 98

April 28, 1998

Cytokine Networks to initiate clinical trial of anticancer vaccine

April 24, 1998

Schering-Plough seeks FDA approval for Intron A combination

April 20, 1998

Mechanism of cytotoxic effect of ImmTher

April 9, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...